Special Issue "Asymmetric Synthesis and Medicinal Chemistry"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 January 2010)

Special Issue Editor

Guest Editor
Prof. Dr. Oliver Reiser
Institut für Organische Chemie, Universität Regensburg, Universitätsstr. 31, 93053 Regensburg, Germany
Website: http://www-oc.chemie.uni-regensburg.de/reiser/index.html
E-Mail: oliver.reiser@chemie.uni-regensburg.de
Phone: +49 (0)941 943 4631(4630)
Fax: +49 (0)941 943 4121
Interests: asymmetric catalysis; stereoselective synthesis; natural product; synthesis; unnatural amino acids; foldamers

Special Issue Information

Dear Colleagues,

Any new drug that¹s chiral is likely to be developed and marketed as a single enantiomer. You win more than you lose with single enantiomers.

This statement from an article in Chem. Eng. News emphasized in 2003 the importance of enantiopure pharmaceuticals. Asymmetric Synthesis and Medicinal Chemistry are areas closely related to each other, and very often fundamental contributions in the development of new asymmetric processes initially disclosed on small scale are transfered in a most impressive way into industrial applications, showing the relevance of those fields for academia and industry alike.

I would like to invite contributions to this special issue of Pharamceuticals "Asymmetric Synthesis and Medicinal Chemistry" as an opportunity to showcase the creativity of leading scientists to tackle the challenges in the development of chiral drugs.

Prof. Dr. Oliver Reiser
Guest Editor

Published Papers (1 paper)

by , , , , , , , , ,  and
Pharmaceuticals 2010, 3(4), 1063-1069; doi:10.3390/ph3041063
Received: 21 December 2009; in revised form: 5 January 2010 / Accepted: 29 March 2010 / Published: 31 March 2010
Show/Hide Abstract | Cited by 1 | PDF Full-text (207 KB) | HTML Full-text | XML Full-text
abstract graphic

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert